0000000001085496

AUTHOR

Giovanni Davì

showing 42 related works from this author

Platelet aggregation, ATP release and cytoplasmic Ca2+ movement: the effects of cloricromene.

1994

A placebo-controlled, double-blind, randomized, cross-over study was performed in 24 healthy volunteers. 12 volunteers received Cloricromene (100mg gastroresistant capsules twice a day) for 7 days, the other volunteers received identical placebo capsules. Subsequently, after a 7-day wash-out period, at day 15, each subject received the other treatment. Blood samples were taken on days 1 and 15 (1st day of each treatment) as well as on days 7 and 21 (7th day of each treatment) before the morning drug administration and 2 and 4 hours later. Platelet aggregation and ATP secretion were studied in whole blood (WB) using ADP and collagen as stimulating agents. Ca2+ fluxes were studied in aequorin…

AdultMaleCytoplasmAdolescentPlatelet Aggregationchemistry.chemical_elementAdministration OralPharmacologyCalciumPlaceboAdenosine TriphosphateDouble-Blind MethodOral administrationHumansPlateletSecretionWhole bloodCalcium metabolismCross-Over StudiesChemistryChromonarHematologyMiddle AgedCrossover studyAdenosine DiphosphateAnesthesiaCalciumFemaleCollagenPlatelet Aggregation InhibitorsThrombosis research
researchProduct

ABNORMALLY HIGH THROMBOXANE BIOSYNTHESIS IN HOMOZYGOUS HOMOCYSTINURIA. EVIDENCE FOR PLATELET INVOLVEMENT AND PROBUCOL-SENSITIVE MECHANISM.

1993

Homocystinuria due to homozygous cystathionine beta-synthase deficiency is an inborn error of metabolism characterized by a high incidence of thrombosis and premature atherosclerosis. We evaluated TXA2 biosynthesis in vivo and several in vitro tests of platelet function in 11 homocystinuric patients and 12 healthy controls. In vitro, patients' platelet aggregation was within control values as were TXB2 formation, fibrinogen binding, and ATP secretion in response to thrombin. In contrast, the urinary excretion of 11-dehydro-TXB2, a major enzymatic derivative of TXA2, was > 2 SD of controls in all patients (1,724 +/- 828 pg/mg creatinine, mean +/- SD, in patients vs. 345 +/- 136 in controls, …

AdultBlood PlateletsMalemedicine.medical_specialtyAdolescentPlatelet AggregationThromboxaneProbucolHomocystinuriaInternal medicinemedicineHumansPlateletPlatelet activationChildBlood CoagulationbiologyAspirinChemistryFibrinolysisHomozygoteFibrinogen bindingThromboxanesGeneral Medicinemedicine.diseaseCystathionine beta synthaseEndocrinologyProbucolbiology.proteinlipids (amino acids peptides and proteins)FemaleHomocystinuriaCyclooxygenasemedicine.drugcirculatory and respiratory physiologyResearch Article
researchProduct

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct

Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina

1991

PAI-1 antigen, tPA antigen and thrombin - antithrombin III complexes (TAT) levels were measured in 10 males with stable angina and type-II diabetes mellitus and in 16 males with stable angina without diabetes or other risk factors (hyperfibrinogenaemia, hyperlipidaemia, diabetes, hypertension, smoking and obesity) known to increase PAI levels. Ten healthy men of equivalent age served as controls. Because only diabetics with coronary artery disease (CAD) showed a decreased fibrinolytic capacity, a second study was performed on the 16 non-diabetic CAD patients to determine whether submaximal workload induces significant changes of tPA and PAI levels. TAT levels were increased in CAD, and sign…

AdultMalemedicine.medical_specialtyAntithrombin IIICoronary DiseaseStable anginaAngina PectorisFibrin Fibrinogen Degradation ProductsCoronary artery diseaseThrombinAntigenDiabetes mellitusInternal medicinemedicineHumanscardiovascular diseasesAgedbusiness.industryFibrinolysisPlasminogen activator inhibitor antigenAntithrombinFibrinogenHematologyGeneral MedicineMiddle Agedmedicine.diseaseObesityPlasminogen InactivatorsEndocrinologyDiabetes Mellitus Type 2Tissue Plasminogen ActivatorExercise TestbusinessPeptide Hydrolasesmedicine.drugBlood Coagulation & Fibrinolysis
researchProduct

The effect of two low doses of aspirin on whole blood thromboxane and prostacyclin generation in healthy subjects

1983

SummaryThe effects of two low doses of aspirin (20 mg and 100 mg) on prostacyclin and thromboxane formation during whole blood clotting were studied in 8 healthy volunteers.A single 100 mg aspirin dose caused more than 90% reduction of both serum TXB2 and 6-keto-PGF1α; a single 20 mg dose of aspirin inhibited serum TXB2 more than 6-keto-PGF1α but effects on these two products could not be completely dissociated.However, the effect of a single 20 mg aspirin dose on serum TXB2, was of much longer duration than its inhibitory effect on PGI2 synthesis during whole blood clotting.

AdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classThromboxaneAlpha (ethology)Prostacyclin6-Ketoprostaglandin F1 alphaInternal medicinemedicineHumansCyclooxygenase InhibitorsBlood CoagulationWhole bloodAspirinAspirinChemistryAnticoagulantLow doseThromboxanesHematologyHeparinEpoprostenolThromboxane B2EndocrinologyFemalelipids (amino acids peptides and proteins)circulatory and respiratory physiologymedicine.drug
researchProduct

Carotid plaque detection improves the predictve value of CHA2DS2-VASc score in patients with non-valvular atrial fibrilation: The ARAPACIS Study

2017

Abstract Background and aims Vascular disease (VD), as assessed by history of myocardial infarction or peripheral artery disease or aortic plaque, increases stroke risk in atrial fibrillation (AF), and is a component of risk assessment using the CHA 2 DS 2 -VASc score. We investigated if systemic atherosclerosis as detected by ultrasound carotid plaque (CP) could improve the predictive value of the CHA 2 DS 2 -VASc score. Methods We analysed data from the ARAPACIS study, an observational study including 2027 Italian patients with non-valvular AF, in whom CP was detected using Doppler Ultrasonography. Results VD was reported in 351 (17.3%) patients while CP was detected in 16.6% patients. Ad…

Atherosclerosis Atrial fibrillation Carotid plaque CHA2DS2-VASc score Stroke Vascular diseaseCarotid Artery DiseasesMaleAtherosclerosis; Atrial fibrillation; Carotid plaque; CHA2DS2-VASc score; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk Assessment; Cardiology and Cardiovascular Medicine030204 cardiovascular system & hematologyatrialf fibrillation0302 clinical medicineRetrospective StudieRisk FactorsCarotid artery diseaseAtherosclerosis; Atrial fibrillation; Carotid plaque; CHA; 2; DS; 2; -VASc score; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk AssessmentAtrial Fibrillation80 and over030212 general & internal medicineMyocardial infarctionStrokeDSAtherosclerosis; Atrial fibrillation; CHA(2)DS(2)-VASc score; Carotid plaque; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk AssessmentCHA 2 DS 2 -VASc scorePlaqueAtheroscleroticUltrasonographyAged 80 and overIncidenceDopplerAtrial fibrillationCarotid plaquePlaque AtheroscleroticStrokeSurvival RateItalyAtherosclerosiCHA(2)DS(2)-VASc scoreCardiologyartherosclerosis; atrial fibrillation; carotid plaque; CHA2DS2-VASc score; stroke; vascular disease; aged; aged 80 and over; ankle brachial index; atrialf fibrillation; carotid artery diseases; female; humans; incidence; italy; male; plaque atherosclerotic; retrospective studies; risk factors; survival rate; ultrasonography doppler; risk assessment; cardiology and cardiovascular medicineFemaleSettore SECS-S/01 - StatisticaCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyCHA2DS2-VASc score2Atherosclerosis; Atrial fibrillation; Carotid plaque; CHA 2 DS 2 -VASc score ; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk Assessment; Cardiology and Cardiovascular MedicineSocio-culturaleVascular diseaseRisk Assessment-VASc score03 medical and health sciencesInternal medicinemedicineHumansAnkle Brachial Indexcardiovascular diseasesRisk factorSurvival rateAgedRetrospective StudiesCarotid Artery DiseaseVascular diseasebusiness.industryRisk FactorUltrasonography Dopplermedicine.diseaseAtherosclerosisartherosclerosisCHA2DS2–VASc scoreCHAAtherosclerosis; Atrial fibrillation; Carotid plaque; CHA; 2; DS; 2; -VASc score; Stroke; Vascular diseasebusiness
researchProduct

Sulfinpyrazone and platelet function in hypertensive patients

1984

Clinical trialmedicine.medical_specialtyPlatelet aggregationbusiness.industrySulfinpyrazoneInternal medicinemedicineCardiologyPlateletHematologybusinessmedicine.drug
researchProduct

Thrombin-antithrombin III complexes in type II diabetes mellitus.

1992

Several studies suggest that diabetes is associated with a hypercoagulable state. Therefore determination of thrombin-antithrombin complex (TAT) could represent a sensitive parameter for specific detection of a latent activation of the clotting system. The present study documents increased plasma TAT in a heterogeneous group of non-insulin-dependent diabetic patients. The finding of increased TAT levels both in diabetic patients with vascular complications and in vascular disease patients without diabetes suggests a relationship between existing vascular disease and the hemostatic mechanism that produces augmented thrombin activity. In acute vascular occlusions the presence of diabetes seem…

AdultMalemedicine.medical_specialtySpecific detectionEndocrinology Diabetes and MetabolismAntithrombin IIIType ii diabetesEndocrinologyReference ValuesDiabetes mellitusInternal medicineInternal MedicinemedicineHumansAgedAged 80 and overHeterogeneous groupVascular diseasebusiness.industryThrombin/Antithrombin IIIAge FactorsThrombinMiddle Agedmedicine.diseaseCerebrovascular DisordersCoagulative necrosisEndocrinologyDiabetes Mellitus Type 2Thrombin activityRegression AnalysisFemalebusinessDiabetic AngiopathiesJournal of diabetes and its complications
researchProduct

Lp(a) levels in patients undergoing aorto-coronary bypass surgery.

1992

The aims of this study were to evaluate plasma lipid, apoprotein and Lp(a) levels in patients with severe coronary atherosclerosis undergoing aorto-coronary bypass surgery (BP) and to relate these parameters to the involvement of one or more vessels. Seventy-seven male patients and 77 cardiovascular disease-free controls, matched for sex, age and body weight were studied. Higher triglyceride and apo B levels with lower HDL-cholesterol and apo A-I levels were found in BP patients in comparison with the controls. Lp(a) levels were slightly, but not significantly, increased. Moreover BP patients presented a significantly higher prevalence of HDL-cholesterol levels below 35 mg dl-1 (49.3% vs 22…

Malemedicine.medical_specialtyApolipoprotein BCoronary Artery DiseaseCoronary artery diseaseInternal medicineMedicineHumansDerivationCoronary Artery BypassCoronary atherosclerosisTriglyceridesAgedApolipoproteins BAnalysis of VarianceChi-Square DistributionbiologyApolipoprotein A-Ibusiness.industryCholesterol HDLLipoprotein(a)Middle Agedmedicine.diseaseStenosisBypass surgeryCoronary vesselbiology.proteinCardiologyCardiology and Cardiovascular MedicinebusinessLipoprotein(a)European heart journal
researchProduct

Platelet Aggregation, Coagulation and Fibrinolysis at Rest and after Bicycle Ergometer Test in CHD

1980

Several observers have suggested that a dysfunction of dynamic balance between platelet aggregation, coagulation and fibrinolysis may be a factor in the pathogenesis of atherosclerosis. This dysfunction, presumably, is correlated with the atherosclerotic vascular lesions, that could reduce the parietal synthesis of heparan-sulphase, prostacyclin and plas minogen activator.

medicine.medical_specialtyPlatelet aggregationbusiness.industryActivator (genetics)medicine.medical_treatmentProstacyclinStable anginaPathogenesisCoagulationInternal medicineFibrinolysisCardiologymedicineBicycle ergometerbusinessmedicine.drug
researchProduct

POSTPRANDIAL HYPERGLYCEMIA IS A DETERMINANT OF PLATELET ACTIVATION IN EARLY 2 DIABETES MELLITUS

2010

BACKGROUND: Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus. OBJECTIVES: To evaluate the effects of acarbose, an alpha-glucosidase inhibitor, on platelet activation and its determinants in newly diagnosed type 2 diabetic patients. METHODS: Forty-eight subjects (26 males, aged 61 +/- 8 years) with early type 2 diabetes (baseline hemoglobin A(1c) < or = 7% and no previous hypoglycemic treatment) were randomly assigned to acarbose up to 100 mg three times a day or placebo, and evaluated every 4 weeks for 20 weeks. The main outcome measures were urinary 11-dehydro-thromboxane (TX)B(2) (marker of in vivo platelet activation) and 8-iso-prostaglandi…

Blood GlucoseMaleTime FactorsSettore MED/09 - Medicina InternaDinoprostpostprandial hyperglycemia; platelet activationMedicineEnzyme InhibitorsSettore MED/49 - Scienze Tecniche Dietetiche Applicatepostprandial hyperglycemiaAcarboseplateletHemoglobin AHematologyMiddle AgedPostprandial PeriodP-SelectinPostprandialTreatment OutcomeC-Reactive ProteinItalyFemaleBiological MarkersAcarboseType 2medicine.drugacarbose platelet activation postprandial hyperglycemia type 2 diabetes mellitusmedicine.medical_specialtySettore BIO/14 - FARMACOLOGIAUrinary systemCD40 LigandGlycosylatedArginineExcretionBlood Glucose; Time Factors; Lipid Peroxidation; Middle Aged; Hemoglobin A Glycosylated; Postprandial Period; Diabetes Mellitus Type 2; Enzyme Inhibitors; Hypoglycemic Agents; P-Selectin; Platelet Activation; Aged; CD40 Ligand; Treatment Outcome; Male; Female; Thromboxane B2; Dinoprost; Italy; Arginine; Acarbose; Double-Blind Method; Humans; Biological Markers; Hyperglycemia; alpha-Glucosidases; C-Reactive ProteinDouble-Blind MethodInternal medicineDiabetes mellitusDiabetes MellitusHypoglycemic AgentsHumansGlycoside Hydrolase InhibitorsPlatelet activationGlycemicAgedGlycated Hemoglobinbusiness.industryType 2 Diabetes Mellitusalpha-Glucosidasesmedicine.diseasePlatelet ActivationThromboxane B2EndocrinologyDiabetes Mellitus Type 2HyperglycemiaLipid PeroxidationbusinessBiomarkers
researchProduct

Circulating immune complexes and platelet thromboxane synthesis in patients with insulin-dependent (type I) diabetes mellitus

1984

Platelets from diabetic subjects with circulating immune complexes (CIC) synthesized greater amounts of thromboxane than did platelets from CIC-negative patients or controls. In view of the known action of CIC on platelet function, a relationship between these two factors may be suggested in the initiation and progression of microangiopathy in diabetes.

Blood PlateletsMalemedicine.medical_specialtyThromboxaneInsulin AntibodiesEndocrinology Diabetes and MetabolismAntigen-Antibody ComplexPathogenesisImmune systemInternal medicineDiabetes mellitusmedicineInternal MedicineHumansPlateletIn patientChildbusiness.industryMicroangiopathyThromboxanesComplement C3medicine.diseaseImmune complexAntibodies Anti-IdiotypicThromboxane B2Diabetes Mellitus Type 1EndocrinologyImmunoglobulin GImmunologyFemalebusinessDiabetes
researchProduct

Association of Inflammation Markers with Impaired Insulin Sensitivity and Coagulative Activation in Obese Healthy Women

2003

Abstract Insulin resistance is associated with a low chronic inflammatory state. In this study we investigated the relationship between impaired insulin sensitivity and selected markers of inflammation and thrombin generation in obese healthy women. We examined 32 healthy obese women (body mass index ≥ 28), with normal insulin sensitivity (NIS, n = 14) or impaired insulin sensitivity (n = 18), and 10 nonobese women (body mass index &amp;lt; 25). Impaired insulin sensitivity patients had significantly higher levels of C-reactive protein (CRP), TGF-β1, plasminogen activator inhibitor-1 (PAI-1), activated factor VII (VIIa), and prothrombin fragment 1 + 2 (F1 + 2) compared with either control s…

Adultmedicine.medical_specialtyobesityEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryPopulationInflammationFactor VIIaBiologyBiochemistryEndocrinologyInsulin resistanceTransforming Growth Factor betaInternal medicineinsulin resistancePlasminogen Activator Inhibitor 1medicineHumansProtein PrecursorseducationBlood CoagulationPancreatic hormoneeducation.field_of_studyInsulinBiochemistry (medical)ThrombinMiddle Agedmedicine.diseaseObesityPeptide FragmentsC-Reactive ProteinEndocrinologyhemostasis; inflammation; insulin resistance; obesityinflammationhemostasisFemaleProthrombinmedicine.symptomBody mass indexPlasminogen activatorBiomarkers
researchProduct

Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.

2004

Abstract Triflusal is an antiplatelet drug related to aspirin, with different pharmacological properties and a lower haemorrhagic risk. We aimed at comparing their effects on platelet and endothelial activation in type 2 diabetes mellitus (T2DM). In a randomized, double-blind, parallel group study, we compared the effects of three daily regimens (300, 600, and 900mg) of triflusal, and aspirin (100mg/day) on urinary 11-dehydro-thromboxane (TX)B 2 , index of in vivo platelet activation, ex vivo platelet function using the analyzer PFA-100, plasma von Willebrand factor (vWF), P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and serum nitrite a…

AdultMalemedicine.medical_specialtyThromboxaneaspirinRadioimmunoassaychemistry.chemical_compoundThromboxane A2Von Willebrand factorDouble-Blind MethodInternal medicinetype 2 diabetes triellitusvon Willebrand Factormedicineplatelet activationHumansPlateletPlatelet activationAgedRetrospective StudiesAspirinbiologyDose-Response Relationship DrugMiddle AgedSalicylatesThromboxane B2Thromboxane B2triflusalP-SelectinEndocrinologychemistryDiabetes Mellitus Type 2biology.proteinTriflusalFemaleCardiology and Cardiovascular MedicineBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFollow-Up Studies
researchProduct

Platelet Activity and Blood Lipid Changes in Diabetes Mellitus

1984

An altered platelet function can often be found in diabetes mellitus (2, 3, 4, 10, 13, 16, 17, 23, 24). Several studies have pointed towards an increased sensitivity of platelets to ADP induced aggregation (3, 6, 23) in diabetic patients; this phenomenon can also be found in diabetics without apparent vasculopathy and in subjects with altered glucose tolerance (3, 23).

medicine.medical_specialtybusiness.industryfood and beveragesBlood lipidsDiabetic retinopathyDiabetic angiopathymedicine.diseaseMalondialdehydechemistry.chemical_compoundEndocrinologychemistryInternal medicineDiabetes mellitusmedicinePlateletPlatelet activationbusinessProstaglandin endoperoxide
researchProduct

Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study

2018

Chronic obstructive pulmonary disease (COPD) increases the risk of mortality in non-valvular atrial fibrillation (NVAF) patients. Data on the relationship of COPD to major cardiovascular events (MACE) in AF have not been defined. The aim of the study is to assess the predictive value of COPD on incident MACE in NVAF patients over a 3-year follow-up. In the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study (ARAPACIS) cohort, we evaluate the impact of COPD on the following clinical endpoints: MACE (including vascular death, fatal/non-fatal MI and stroke/TIA), cardiovascular (CV) death and all-cause mortality. Among 2027 NVAF patients, pati…

MaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologyPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsMajor cardiovascular eventCause of DeathRisk of mortalityPrevalenceMedicine030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyStrokeCause of deathCOPDChronic obstructive pulmonary diseaseIncidenceHazard ratioAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular events; Aged; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Endpoint Determination; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Predictive Value of Tests; Prevalence; Prospective Studies; Pulmonary Disease Chronic Obstructive; Registries; Risk Factors; Internal Medicine; Emergency MedicineAtrial fibrillationAtrial fibrillation Cardiovascular mortality Chronic obstructive pulmonary disease Major cardiovascular eventsItalyCardiovascular DiseasesCardiologyEmergency MedicineFemaleSettore SECS-S/01 - Statisticamedicine.medical_specialtyChronic ObstructiveCardiovascular mortalityEndpoint DeterminationAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular events; Aged; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Endpoint Determination; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Predictive Value of Tests; Prevalence; Prospective Studies; Pulmonary Disease Chronic Obstructive; Registries; Risk FactorsSocio-culturalePulmonary Disease03 medical and health sciencesPredictive Value of TestsInternal medicineInternal MedicineHumanscardiovascular diseasesAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular eventsAgedbusiness.industryMajor cardiovascular eventsmedicine.diseaseAtrial fibrillationAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular events; Internal Medicine; Emergency MedicinebusinessMaceFollow-Up Studies
researchProduct

Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus

2003

Background— To investigate early events possibly related to the development of diabetic angiopathy, we examined whether 8-iso-prostaglandin F 2α (8-iso-PGF 2α ) formation, a marker of in vivo oxidant stress, is altered in different stages of type 1 diabetes (T1DM) and whether it correlates with the rate of thromboxane (TX) A 2 biosynthesis, a marker of in vivo platelet activation. We also investigated the relationship between inflammatory markers and F 2 -isoprostane formation in this setting. Methods and Results— A cross-sectional study was performed in 23 insulin-treated patients aged &lt;18 years with new-onset T1DM (≤6 weeks, group A), matched for age and gender with 23 patients with s…

diabetes mellitus; inflammation; plateletsMalemedicine.medical_specialtyAdolescentThromboxaneInflammationDiabetic angiopathyDinoprostTimeThromboxane A2Reference ValuesPhysiology (medical)Internal medicineDiabetes mellitusHumansInsulinMedicinePlatelet activationChildInterleukin 6InflammationF2-IsoprostanesType 1 diabetesbiologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryPlatelet Activationmedicine.diseaseThromboxane B2Oxidative StressC-Reactive ProteinCross-Sectional StudiesDiabetes Mellitus Type 1Endocrinologydiabetes mellitusplateletsDisease Progressionbiology.proteinFemaleTumor necrosis factor alphaLipid Peroxidationmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesCirculation
researchProduct

Platelet Function Changes In Acute Myocardial Infarction

1981

Whether the thrombotic component of myocardial infarction is primary or secondary in a given patient, platelet function alterations can influence many mechanism from which depends if the thrombotic lesion grows or sends platelet emboli to the smaller myocardial vessels. Recently in some cases of infarction, coronary artery spasm has been demonstrated angiographically; thromboxanes, vasoconstrictive and platelet-aggregating substances, are released by platelets during myocardial ischemia. The local release of these substances may modify the myocardial cell viability and regional blood flow.The aim of the present study was to investigate changes in platelet function in relation to the time in…

medicine.medical_specialtybusiness.industryInternal medicineCardiologyMedicinePlateletMyocardial infarctionbusinessmedicine.diseaseFunction (biology)Oral Presentations
researchProduct

Chronic Administration of Slow-Release Nifedipine Improves Arterial Compliance in Elderly Hypertensives with Systolic Hypertension

1988

medicine.medical_specialtySystolic hypertensionbusiness.industryGeneral Neurosciencemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyCompliance (physiology)History and Philosophy of ScienceNifedipineInternal medicinemedicineCardiologybusinessAdministration (government)medicine.drugAnnals of the New York Academy of Sciences
researchProduct

Effects of sorbinicate and nicotinic acid on blood viscosity, red cell deformation and platelet function

1982

Summary Nicotinic acid (NA) and a retard derivative, sorbinicate, were investigated for their effects on blood rheology and platelet function, after oral administration, in two groups of patients with lower limb atherosclerosis obliterans — the second group having diabetes also. Red cell deformation and blood plasma viscosity were studied in the nondiabetic group (single dose of NA, 100 mg, and sorbinicate, 400 mg); release of platelet malondialdehyde (MDA) (single dose of NA, 100 mg, and sorbinicate, 800 mg), and the platelet regeneration time (before and after sorbinicate 400 mg × 3/die for 7 days) were studied in the diabetic group. Both drugs induced a significant improvement in red cel…

AdultBlood PlateletsMalemedicine.medical_specialtyErythrocytesTime FactorsBlood viscosityNiacinchemistry.chemical_compoundNEFAOral administrationMalondialdehydeInternal medicineDiabetes mellitusBlood plasmamedicineHumansSorbitolPlateletTriglyceridesPharmacologyRed CellChemistryNicotinic AcidsFibrinogenMiddle AgedBlood Viscositymedicine.diseaseMalondialdehydeCholesterolEndocrinologyBiochemistryFemalePharmacological Research Communications
researchProduct

Determinants of enhanced thromboxane biosynthesis in renal transplantation

2001

Determinants of enhanced thromboxane biosynthesis in renal transplantation.BackgroundDespite great improvement in patient and graft survival, the long-term morbidity and mortality in renal transplant recipients (RTRs) are still significant, with a high incidence of cardiovascular disease-related deaths.MethodsWe investigated thromboxane (TXA2) biosynthesis and endothelial and coagulative activation in 65 patients who received a renal transplant.ResultsThe rate of TXA2 biosynthesis (urinary 11-dehydro-TXB2 excretion largely reflects platelet TXA2 production in vivo) was significantly (P < 0.0001) higher in RTRs than in healthy subjects. Plasma von Willebrand factor (vWF) and thrombin-antithr…

MaleSettore MED/09 - Medicina InternaThromboxanegraft survivalThromboxanevon Willebrand factorImmunosuppressive AgentThromboxane A2chemistry.chemical_compoundReference ValuesRenal Dialysicardiovascular diseaseReference ValuePlateletPostoperative PeriodKidney transplantationKidneyimmunosuppressionnephrotoxicityThromboxanesMiddle AgedCholesterolmedicine.anatomical_structureNephrologyCyclosporineFemaleCardiovascular disease; Graft survival; Immunosuppression; Kidney transplantation; Nephrotoxicity; Von Willebrand factor; Adult; Antithrombin III; Cardiovascular Diseases; Cholesterol; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Peptide Hydrolases; Postoperative Period; Reference Values; Renal Dialysis; Thromboxanes; von Willebrand Factor; Kidney Transplantation; NephrologyImmunosuppressive AgentsHumancirculatory and respiratory physiologyAdultmedicine.medical_specialtyAntithrombin IIIUrologykidney transplantationFollow-Up StudieEndothelial activationRenal DialysismedicineHumansPlatelet activationcardiovascular disease; cardiovascular diseases; graft survival; immunosuppression; kidney transplantation; nephrotoxicity; von willebrand factorbusiness.industrymedicine.diseasecardiovascular diseasesTransplantationPeptide HydrolasechemistryImmunologybusinessFollow-Up StudiesPeptide HydrolasesKidney International
researchProduct

Platelet Activity in Relation to Smoke and Exercise in Patients with Chronic Obstructive Lung Disease: Effects of Platelet Antiaggregating Drugs

1984

Lung tissue is involved in the synthesis and/or metabolism of many vasoactive substances such as histamine, serotonin, dopamine, norepinephrine, bradikinin, angiotensin II and prostaglandins (1).

medicine.medical_specialtybusiness.industryPharmacologymedicine.diseaseAngiotensin IIObstructive lung diseaseNorepinephrine (medication)chemistry.chemical_compoundchemistryDopamineInternal medicinemedicineCardiologyPlateletSerotoninPlatelet activationbusinessHistaminemedicine.drug
researchProduct

Platelet Function Changes in Acute Myocardial Infarction

1984

Whether the thrombotic component of myocardial infarction is primary or secondary in a given patient, platelet function alterations can influence many mechanisms — operating at the microenvi-ronmental level — from which it depends if the thrombotic lesion grows or sends platelet emboli to the smaller myocardial vessels.

medicine.medical_specialtyPlatelet aggregationbusiness.industrymedicine.diseaseLesionInternal medicinecardiovascular systemmedicineCardiologyPlateletcardiovascular diseasesSpontaneous platelet aggregationMyocardial infarctionmedicine.symptombusiness
researchProduct

No evidence of platelet activation in obesity.

1993

AdultMalemedicine.medical_specialtybusiness.industryHematologyMiddle Agedmedicine.diseasePlatelet ActivationObesityEndocrinologyInternal medicinemedicineHumansFemalePlatelet activationObesitybusinessThrombosis and haemostasis
researchProduct

Estimated Glomerular Filtration Rate Is an Easy Predictor of Venous Thromboembolism in Cancer Patients Undergoing Platinum-Based Chemotherapy

2014

Abstract Background. Reduced estimated glomerular filtration rate (eGFR) has been associated with increased venous thromboembolism (VTE) risk in the general population. VTE incidence significantly increases in cancer patients, especially those undergoing chemotherapy. Despite the evidence that a substantial number of cancer patients have unrecognized renal impairment, as indicated by reduced eGFR in the presence of serum creatinine levels within the reference value, chemotherapy dosage is routinely adjusted for serum creatinine values. Among chemotherapies, platinum-based regimens are associated with the highest rates of VTE. A cohort study was designed to assess the value of pretreatment e…

MaleOncologyCancer ResearchSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPlatinum CompoundsPlatinum-based chemotherapy; Renal impairment; Risk prediction; Risk stratification; Toxicity; Venous thromboembolism; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Neoplasms; Platinum Compounds; Venous Thromboembolism; Young Adult; Cancer Research; Oncology; Medicine (all)Platinum CompoundKidneyAntineoplastic AgentCohort Studieschemistry.chemical_compoundNeoplasmsRenal impairmentPlatinum-based chemotherapyAged 80 and overeducation.field_of_studyMedicine (all)Hazard ratioVenous ThromboembolismMiddle AgedRisk predictionOncologySymptom Management and Supportive CareCreatinineCohortFemaleHumanGlomerular Filtration RateCohort studyAdultmedicine.medical_specialtyPopulationRenal functionAntineoplastic AgentsYoung AdultInternal medicinemedicineHumanscardiovascular diseaseseducationRisk stratificationAgedChemotherapyCreatinineToxicitybusiness.industryCancerRenal impairment; Risk stratification; Venous thromboembolism; Risk prediction; Toxicity; Platinum-based chemotherapymedicine.diseaseSurgerychemistryNeoplasmCohort StudiebusinessThe Oncologist
researchProduct

Platelets, eicosanoids and aging.

1992

Aged 80 and overBlood Plateletsmedicine.medical_specialtyAgingPlatelet AggregationGeriatrics gerontologybusiness.industrymedicine.diseaseThrombosisEndocrinologyInternal medicinemedicineBlood VesselsEicosanoidsHumansPlateletGeriatrics and GerontologybusinessAgedAging (Milan, Italy)
researchProduct

Influence of Metabolic Control on Thromboxane Biosynthesis and Plasma Plasminogen Activator Inhibitor Type-1 in Non-insulin-dependent Diabetes mellit…

1996

SummaryWe have previously shown that tight metabolic control by insulin therapy reduced thromboxane-dependent platelet activation in noninsulin-dependent diabetes mellitus (NIDDM) patients. The present study was undertaken to determine whether a similar effect could be obtained without switching diabetics in secondary failure to insulin treatment. For this purpose, we gave strict diet and exercise advise program and adjusted on a weekly basis the oral antidiabetic therapy (glipizide) that 26 patients with NIDDM had been given over the previous months.Basal measurements of urinary ll-dehydro-TXB2 and PAI-1 confirmed previous findings of enhanced levels of these parameters in NIDDM patients w…

medicine.medical_specialtybusiness.industryThromboxaneInsulinmedicine.medical_treatmentHematologymedicine.diseasechemistry.chemical_compoundEndocrinologychemistryBasal (medicine)Plasminogen activator inhibitor-1Diabetes mellitusInternal medicineMetabolic control analysismedicinePlatelet activationbusinessMacrovascular diseaseThrombosis and Haemostasis
researchProduct

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

2017

Background and aims Blood lysosomal acid lipase (LAL) is reduced in non-alcoholic steatohepatitis, which is the major cause of cryptogenic cirrhosis (CC); few data on LAL activity in CC do exist. We investigated LAL activity in a cohort of patients with liver cirrhosis. Methods This is a multicentre cohort study including 274 patients with liver cirrhosis of different aetiology from 19 centres of Internal Medicine, Gastroenterology and Hepatology distributed throughout Italy. Blood LAL activity (nmol/spot/h) was measured with dried blood spot extracts using Lalistat 2. Results Overall, 133 patients had CC, and 141 patients had cirrhosis by other causes (61 viral, 53 alcoholic, 20 alcoholic …

Liver CirrhosisMaleCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; PathogenesisCirrhosisCryptogenic cirrhosisCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Cardiology and Cardiovascular MedicineComorbidityPathogenesisLysosonal acid lipase; non-alcoolic fatty liver disease; cirrhosis030204 cardiovascular system & hematologyGastroenterologyLiver disease0302 clinical medicineModel for End-Stage Liver DiseasePathogenesiRisk FactorsPrevalenceProspective cohort studyMultivariate AnalysiSettore MED/12 - GastroenterologiaMiddle AgedItalyCohortLinear Model030211 gastroenterology & hepatologyFemaleCardiology and Cardiovascular MedicineLiver diseaseHumanmedicine.medical_specialtyLiver CirrhosiDown-Regulation03 medical and health sciencesInternal medicineCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Aged; Biomarkers; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Down-Regulation; Dried Blood Spot Testing; Female; Humans; Italy; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prevalence; Risk Factors; Sterol EsterasemedicineLysosonal acid lipaseHumansnon-alcoolic fatty liver diseaseAgedCross-Sectional StudieChi-Square Distributionbusiness.industryPlatelet CountcirrhosisRisk FactorBiomarkerCholesterol ester storage diseaseHepatologySterol Esterasemedicine.diseaseCross-Sectional StudiesMultivariate AnalysisLysosomal acid lipaseLinear ModelsDried Blood Spot TestingSteatohepatitisbusinessCryptogenic cirrhosiBiomarkers
researchProduct

Platelet Function Tests and Coronary Heart Disease

1984

It is well known that the formation of a platelet aggregate is the first step in an arterial thrombotic process.

medicine.medical_specialtyFramingham Risk ScoreEndotheliumPlatelet aggregationbusiness.industryeducationmedicine.diseaseCoronary heart diseasestomatognathic diseasesmedicine.anatomical_structurePlatelet function testPlatelet adhesivenessInternal medicinemedicineCardiologyPlateletMyocardial infarctionbusiness
researchProduct

Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins

2007

The receptor for advanced glycation endproducts (RAGE) is overexpressed at sites of vascular pathology. A soluble RAGE isoform (sRAGE) neutralizes the ligand-mediated damage by acting as a decoy. We hypothesized that in hypercholesterolemia up-regulation of the ligand-RAGE axis may bridge impairment of nitric oxide biosynthesis with oxidative stress. We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (ADMA). The effects of two structurally different statins (pravastatin and atorvastatin) on these parameters were analyzed in 20 hypercholesterolemic su…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaStatinmedicine.drug_classAtorvastatinHypercholesterolemiaReceptor for Advanced Glycation End ProductsFree radicalsArginineDinoprostNitric Oxidemedicine.disease_causeBiochemistrychemistry.chemical_compoundDouble-Blind MethodPhysiology (medical)Internal medicineHyperlipidemiaAtorvastatinmedicineHumansPyrrolesReceptors ImmunologicEndothelial dysfunctionPravastatinChemistryVascular diseaseAnticholesteremic AgentsStatinnutritional and metabolic diseasesMiddle AgedAtherosclerosismedicine.diseaseADMACross-Sectional StudiesHyperlipidemiaEndocrinologyHeptanoic AcidsOxidative streFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsNitric Oxide SynthaseAsymmetric dimethylarginineOxidative stressPravastatinsRAGEmedicine.drugFree Radical Biology and Medicine
researchProduct

Fibrinogen and von Willebrand factor in type II diabetes mellitus

1992

A hypercoagulable state may contribute to the formation of early vascular lesions in diabetes. The von Willebrand factor is required for the attachment of platelets to the subendothelium; fibrinogen is required for platelet aggregation. This study was designed to assess in type II diabetic patients plasma levels of fibrinogen and von Willebrand factor to see if these variables are associated with platelet aggregation responses to adenosine diphosphate (ADP). Fibrinogen and the von Willebrand factor were significantly increased in diabetics but only fibrinogen was significantly related to platelet aggregation for ADP. Strict metabolic control does not reduce the increased concentrations of t…

medicine.medical_specialtybiologybusiness.industryEndocrinology Diabetes and MetabolismGeneral MedicineFibrinogenmedicine.diseaseAdenosine diphosphatechemistry.chemical_compoundEndocrinologyEndocrinologychemistryVon Willebrand factorInternal medicineMetabolic control analysisDiabetes mellitusInternal Medicinebiology.proteinMedicinePlateletRisk factorbusinessmedicine.drugMacrovascular diseaseActa Diabetologica
researchProduct

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study

2016

Background: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths. Methods: Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 European Society of Cardiology (ESC) guidelines is associated to a lower rate of adverse outcomes. Data were obtained from REPOSI; a prospective observational study enrolling inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis were analysed. Results: Among 2535 patients, 558 (22.0 %) were discharged with a diagnos…

Antithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Cardiology and Cardiovascular MedicineMaleRegistrieTime Factorsantithrombotic therapy; atrial fibrillation; elderly; guidelines; outcomesAtrial fibrillation (AF)Practice PatternsKaplan-Meier Estimate030204 cardiovascular system & hematologyGuidelineoutcomesCoronary artery disease0302 clinical medicineElderlyRisk FactorsAtrial FibrillationAntithrombotic80 and overAge Factor030212 general & internal medicineRegistriesguidelinesAntithrombotic therapy Atrial fibrillation Elderly Guidelines OutcomesPractice Patterns Physicians'OutcomeAged 80 and overFibrinolytic AgentAge FactorsAtrial fibrillationGeneral MedicineTreatment OutcomeItalyAtrial fibrillation (AF) thromboembolism antithrombotic prophylaxisPractice Guidelines as TopicCardiologyFemaleGuideline AdherenceCardiology and Cardiovascular MedicineHumanAntithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Age Factors; Aged; Aged 80 and over; Atrial Fibrillation; Chi-Square Distribution; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Practice Patterns Physicians'; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Practice Guidelines as Topic; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyLogistic ModelTime FactorSocio-culturaleLower riskRisk Assessment03 medical and health sciencesFibrinolytic AgentsInternal medicineThromboembolismmedicineHumansProportional Hazards ModelsAgedAntithrombotic therapyPhysicians'Chi-Square Distributionbusiness.industryProportional hazards modelRisk FactorSettore MED/09 - MEDICINA INTERNAGuidelinethromboembolismmedicine.diseaseAtrial fibrillationLogistic ModelsProportional Hazards Modelantithrombotic prophylaxisbusinessChi-squared distributionFibrinolytic agent
researchProduct

Effects of Flurbiprofen on Platelet Function in Ihd Patients

1983

business.industryFlurbiprofenmedicinePlateletPharmacologyCardiology and Cardiovascular MedicinebusinessFunction (biology)medicine.drugEuropean Heart Journal
researchProduct

High serum CXCL10 in Rickettsia conorii infection is endothelial cell ă mediated subsequent to whole blood activation

2016

International audience; Background: The pathophysiological hallmark of Rickettsia conorii (R. ă conorii) infection comprises infection of endothelial cells with ă perivascular infiltration of T-cells and macrophages. Although ă interferon (IFN)-gamma-induced protein 10 (IP-10)/CXCL10 is induced ă during vascular inflammation, data on CXCL10 in R. conorii infection is ă scarce. ă Methods: Serum CXCL10 was analyzed in two cohorts of southern European ă patients with R. conorii infection using multiplex cytokine assays. The ă mechanism of R. conorii-induced CXCL10 release was examined ex vivo ă using human whole blood interacting with endothelial cells. ă Results: (i) At admission, R. conorii …

0301 basic medicineAdultMalemedicine.medical_treatmentT-Lymphocytes030106 microbiologyImmunologyInflammationBiologyBoutonneuse FeverBiochemistryMonocytesCohort Studies03 medical and health sciencesBlood serum[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesmedicineImmunology and AllergyCXCL10HumansInterleukin 8Molecular BiologyWhole bloodAgedAged 80 and overEndothelial CellsHematologyMiddle Agedbiology.organism_classification3. Good healthEndothelial stem cellChemokine CXCL10Rickettsia conorii030104 developmental biologyCytokineImmunologyFemalemedicine.symptomRickettsia conorii
researchProduct

Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients

1982

SummaryIn 13 type II hyperlipidemics (10 males and 3 females; mean age 50.2 ± 10.6 years), in 10 type IV hyperlipidemics (7 males and 3 females; mean age 51 ± 13.3 years) and in 23 healthy age-and sex-matched controls, the following parameters were measured: plasma cholesterol; plasma TG; plasma C-HDL; VLDL, separated in a preparative ultracentrifuge; C-LDL; Apo B, with immunoelectrophoretic method; platelet sensitivity to prostacyclin; TXB2 formation in PRP; TXB2 in serum.This study provides evidence for: 1. Reduced platelet sensitivity to prostacyclin, more evident in type II hyperlipidemia that provides an additional mechanism involved in increased platelet aggregation found in type II h…

medicine.medical_specialtyVery low-density lipoproteinApolipoprotein BbiologyChemistryProstacyclinStimulationHematologyThromboxane ProductionEndocrinologyThrombinInternal medicinemedicinebiology.proteinlipids (amino acids peptides and proteins)PlateletThromboxane-A synthasemedicine.drug
researchProduct

Factor VII Activity Is an Independent Predictor of Cardiovascular Mortality in Elderly Women of a Sicilian Population: Results of an 11-year Follow-up

2002

SummaryThe aim of the Epidemiological project “Ventimiglia di Sicilia” is to identify the cardiovascular risk factors in a Sicilian population with a low risk profile and healthy nutritional habits. The risk of cardiovascular mortality in older subjects (over 60 years of age) is presented for an 11 year follow-up. Females showed higher prevalence of diabetes mellitus, hypertension, obesity and higher levels of total, LDL and HDL cholesterol, factor VII activity and fibrinogen compared to males. Cardiovascular mortality was related to hypertension and obesity in males, to high factor VII activity, obesity and diabetes mellitus in females. In a Logistic Regression model the same variables wer…

MaleSettore MED/09 - Medicina InternaEpidemiologyComorbidityLogistic regressionFibrinogenCohort Studieschemistry.chemical_compoundRisk FactorsEpidemiologyPrevalenceFactor VII activityLipoproteinSicilyeducation.field_of_studyFactor VIISmokingAge FactorsHematologyFactor VIIMiddle AgedCardiovascular diseaseCardiovascular DiseasesHypertensionFemalemedicine.drugAdultRiskmedicine.medical_specialtyHypercholesterolemiaPopulationHyperlipoproteinemia Type IISex FactorsDiabetes mellitusDiabetes MellitusmedicineHumansObesityeducationAgedCoagulationbusiness.industryCholesterolmedicine.diseaseObesitySurgerychemistrybusinessFollow-Up StudiesDemographyThrombosis and Haemostasis
researchProduct

Increased thromboxane biosynthesis in type IIa hypercholesterolemia.

1992

BACKGROUND Increased platelet thromboxane (TX)A2 production has been described in type IIa hypercholesterolemia. To verify the relevance of these capacity-related measurements to the actual rate of TXA2 biosynthesis in vivo, we studied the urinary excretion of its major enzymatic metabolites in 46 patients with type IIa hypercholesterolemia and 20 age-matched controls. METHODS AND RESULTS Urinary 11-dehydro-TXB2 and 2,3-dinor-TXB2 were measured by previously validated radioimmunoassays. The excretion rate of 11-dehydro-TXB2 was significantly (p less than 0.001) higher in patients (68.7 +/- 35.1 ng/hr, mean +/- SD) than in controls (22.4 +/- 9.4 ng/hr), with metabolite excretion greater tha…

AdultBlood PlateletsMalemedicine.medical_specialtySimvastatinThromboxaneMetaboliteHypercholesterolemiaExcretionchemistry.chemical_compoundThromboxane A2Physiology (medical)Internal medicinemedicineHumansPlateletPlatelet activationLovastatinAgedbiologyAspirinDose-Response Relationship Drugbusiness.industryCholesterolAnticholesteremic AgentsMiddle AgedEndocrinologychemistrySimvastatinbiology.proteinlipids (amino acids peptides and proteins)FemaleCyclooxygenaseCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

1995

Abstract Thromboxane A 2 (TXA 2 ) biosynthesis is enhanced in the majority of patients with type IIa hypercholesterolemia. Because simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) was previously shown to reduce platelet aggregation and TXB 2 production ex vivo, we investigated TXA 2 biosynthesis and platelet function in 24 patients with type IIa hypercholesterolemia randomized to receive in a double-blind fashion simvastatin (20 mg/d) or placebo for 3 months. The urinary excretion of 11-dehydro-TXB 2 , largely a reflection of platelet TXA 2 production in vivo, was measured by a previously validated radioimmunoassay technique. Blood lipid levels and urinary 11-dehyd…

AdultMaleBlood lipoproteinSimvastatinmedicine.medical_specialtyPlatelet AggregationApolipoprotein BThromboxaneHypercholesterolemiaBlood lipidsThromboxane A2chemistry.chemical_compoundThromboxane A2Double-Blind MethodInternal medicinemedicineHumansPlateletLovastatinAgedbiologyChemistryCholesterolAnticholesteremic AgentsMiddle AgedLipid MetabolismCholesterolEndocrinologySimvastatinbiology.proteinFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinePlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Hemostatic Alterations in Peripheral Arteriopathies

1985

The most common cause of obliterative disease in limb arteries is slowly progressive arteriosclerosis which is eventually superimposed by thrombosis.

Pathologymedicine.medical_specialtybusiness.industryMedicinePlatelet activationArteriosclerosisDiseasebusinessmedicine.diseaseThrombosisPeripheral
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct

Heart failure and chronic kidney disease in a registry of internal medicine wards

2014

Background: The aim of the present study was to evaluate the association between heart failure (HF) and chronic kidney disease (CKD) in tertiary care centers using the clinical records of patients enrolled in internal medicine departments.Patients and methods: We used the clinical records of 1380 elderly patients to identify patients with a history of HF and CKD using admission ICD codes and glomerular filtration rate (GFR) formulas. Magnitude and strength of such associations were investigated by univariable and multivariable analysis.Results: Of the 1380 patients enrolled, 27.9% had HF (age 80 ± 7, BMI 27 ± 6 kg/m2) and 17.4% CKD (age 81 ± 7, BMI 26.8 ± 6 kg/m2). Both groups were signific…

medicine.medical_specialtyChronic kidney disease; Elderly; Heart failure; REPOSI; Gerontology; Geriatrics and GerontologyHeart failure; Elderly; Chronic kidney disease; REPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Gerontology; Geriatrics and GerontologyChronic kidney disease; Elderly; Heart failure; REPOSIRenal functionHeart failure; chronic kidney disease; elderly; registry; REPOSIHeart failureregistryTertiary careSleep Apnea SyndromeElderlySleep Apnea SyndromesInternal medicineChronic kidney diseaseEpidemiologymedicineHumansNoninvasive Ventilationbusiness.industryREPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Geriatrics and Gerontology; Gerontologymedicine.diseaseHeart failureHeart failure Elderly Chronic kidney disease REPOSIIcd codesGeriatrics and GerontologybusinessClinical recordBody mass indexGerontologyKidney diseaseHuman
researchProduct

Increased expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental Rickettsia conorii infection

2013

Background: Based on their essential role in concerting immunological and inflammatory responses we hypothesized that the homeostatic chemokines CCL19 and CCL21 may play a pathogenic role in rickettsiae infection. Methods: Serum levels of CCL19 and CCL21 in patients with R. africae and R. conorii infection were analyzed by enzyme immunoassays. Lungs from R. conorii infected mice were examined for CCL19, CCL21 and CCR7 expression by immunohistochemistry. Results: We found that patients with R. africae infection (n = 15) and in particular those with R. conorii infection (n = 16) had elevated serum levels of CCL19 on admission, with a decline during follow-up. While a similar pattern was seen …

AdultMaleReceptors CCR7Chemokineendocrine systemR. africaeInflammationC-C chemokine receptor type 7ImmunofluorescencePathogenesisMiceYoung AdultmedicineAnimalsHomeostasisHumansAgedInflammationMice Inbred C3HR. conoriiChemokine CCL21biologymedicine.diagnostic_testCCL19Rickettsia InfectionsMiddle Agedbiology.organism_classificationUp-RegulationRickettsia conoriiInfectious DiseasesImmunologybiology.proteinChemokine CCL19FemaleChemokinesmedicine.symptomRickettsia conoriiImmunostainingResearch ArticleCCR7
researchProduct